Collateral damage of COVID-19 pandemic on oncology clinical trials.

Tella, Sri Harsha; Kommalapati, Anuhya; Alberts, Steve R; McWilliams, Robert; Mahipal, Amit

Tella, Sri Harsha; Kommalapati, Anuhya; Alberts, Steve R; McWilliams, Robert; Mahipal, Amit.

Tella SH; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Kommalapati A; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Alberts SR; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
McWilliams R; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Mahipal A; Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Mahipal.amit@mayo.edu.

Chin Clin Oncol ; 9(6): 80, 2020 12.

Article in English | MEDLINE | ID: covidwho-940448

Subject(s)

COVID-19/diagnosis; Carrier State/diagnosis; Clinical Trials as Topic; Medical Oncology; Neoplasms/therapy; COVID-19/immunology; COVID-19 Nucleic Acid Testing/methods; Coronavirus Envelope Proteins/genetics; Coronavirus Nucleocapsid Proteins/genetics; Humans; Immune Checkpoint Inhibitors/therapeutic use; Immunotherapy, Adoptive/methods; Neoplasms/immunology; Patient Participation; Phosphoproteins/genetics; SARS-CoV-2; Sensitivity and Specificity

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Carrier State / Clinical Trials as Topic / COVID-19 / Medical Oncology / Neoplasms Type of study: Diagnostic study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Chin Clin Oncol Year: 2020 Document Type: Article Affiliation country: Cco-20-200

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google